Expression of cancer-associated molecules in malignant mesothelioma

Our plain-English summary of Expression of cancer-associated molecules in malignant mesothelioma, by B. Davidson (Biomarker Insights, 2007).

The study

• Author: B. Davidson
• Journal: Biomarker Insights
• Published: 2007;2:173-84
• Cited by: 2 articles, as counted by NIH iCite
• Read it: PubMed · Free full text

Abstract

Malignant mesothelioma (MM) is a malignant tumor derived from mesothelial cells, native cells of the body cavities. Exposure to asbestos is the most strongly established etiologic factor, predominantly for the most common disease form, pleural mesothelioma. The pathogenesis of MM involves the accumulation of extensive cytogenetic changes, as well as cancer-related phenotypic alterations that facilitate tumor cell survival, invasion and metastasis. This review presents current knowledge regarding the biological characteristics of this disease that are linked to the so-called hallmarks of cancer. In addition, data suggesting that the anatomic site (solid tumor vs. effusion) affects the expression of metastasis-associated and regulatory molecules in MM are presented. Finally, recent work in which high-throughput methodology has been applied to MM research is reviewed. The data obtained in the reviewed research may aid in defining new prognostic markers and therapeutic targets for this aggressive disease in the future.

In plain English

This is a single-author narrative review, not a new study, although the journal labels it original research. The author reviewed published research on malignant mesothelioma, mainly studies of clinical specimens. The review covered cancer-related features such as protein-degrading enzymes, growth factors, cell survival, cell signaling, the immune response and large-scale gene studies. The review did not study exposure, but it cited laboratory studies in which asbestos affected cell signaling and inhibited killer immune cells. Citing an earlier review, the author noted that 21 of 31 papers published between 2002 and that review's publication found no evidence, or only rare evidence, of the virus SV40 in mesothelioma. The author also summarized earlier studies by the author's own group. One, of 112 mesotheliomas, found significantly higher XIAP expression in peritoneal than in pleural tumors. Another found similar MAPK signaling in mesothelioma cells and in reactive (benign) mesothelial cells. The author concluded that the group's data show differences between peritoneal and pleural mesothelioma, and between tumor cells in solid lesions and in effusions. The author took this to suggest that the tumor environment partly regulates these molecules.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Narrative review of published research (single author); no new data were collected
• Who was studied: Published laboratory research on malignant mesothelioma, mainly studies of clinical specimens (solid tumors and effusions), plus cell-line and experimental studies; this article did not study a patient population of its own
• Exposure: Not studied by this article. Asbestos appears as background, in a cited figure for how often exposure is documented. It also appears in brief citations of other researchers' laboratory studies of how cells respond to asbestos, covering MAPK signaling, EGFR and killer-cell activity.
• Main results:
  • The review cited laboratory studies by other researchers. In these, asbestos affected MAPK signaling and inhibited the activity of lymphocyte-activated killer (LAK) cells in vitro.
  • Citing an earlier review (Shah), the article reported that 21 of 31 papers published between 2002 and the publication of that review either failed to find evidence of SV40 in mesothelioma or found only rare DNA or protein expression of the virus
  • Summarizing an earlier study by the author's group (Kleinberg, 2007), the review reported that immunohistochemical analysis of 112 mesotheliomas showed significantly higher XIAP expression in peritoneal compared to pleural mesothelioma, and in effusions compared to solid lesions
  • Summarizing an earlier study by the author's group (Vintman, 2005), the review reported that mesothelioma cells and reactive mesothelium cells showed similar MAPK expression and activation
  • The author judged that mesothelin has limited value as a diagnostic marker for mesothelioma, because it is also expressed in lung and ovarian adenocarcinoma
• The authors' conclusion: The author concluded that the group's own data show differences between peritoneal and pleural mesothelioma, and between tumor cells in solid lesions and in effusions. The author suggested that the tumor microenvironment partly regulates the production of cancer-associated molecules in mesothelioma.

Topics

Medical terms in this study, explained in our Lexicon: Mesothelioma, Mesothelial Cells, Pleural Mesothelioma, Metastasis.

Related studies

• Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma — S.J. Han, G. Reis, et al. (2016)
• Expression of cell adhesion molecules and connexins in gap junctional intercellular communication deficient human mesothelioma tumour cell lines and communication competent primary mesothelial cells — K. Pelin, A. Hirvonen, et al. (1994)
• NCAM (neural cell adhesion molecules) expression in malignant mesotheliomas — S. Lantuéjoul, M.H. Laverrière, et al. (2000)
• Expression of neural cell adhesion molecule L1 (CD171) in neuroectodermal and other tumors: An immunohistochemical study of 5155 tumors and critical evaluation of CD171 prognostic value in gastrointestinal stromal tumors — S. Inaguma, Z. Wang, et al. (2016)
• Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia — G. Alì, N. Borrelli, et al. (2013)
• Epithelial Cell Adhesion Molecule (EpCAM) Expression in Human Tumors: A Comparison with Pan-Cytokeratin and TROP2 in 14,832 Tumors — A. Menz, N. Lony, et al. (2024)

Browse return to medical research.